Skip to main content
RLYB logo

Rallybio Corporation (RLYB) Stock Price & Analysis

Rallybio Corporation (RLYB) — MoonshotScore 82/100 (Exceptional band), calculated Nov 18, 2026. Price $15.47 (-0.32%), as of the Nov 20, 2026 trading session; market cap $86.6M.

Educational signal · not a buy or sell recommendation · How to read this

$15.47 −$0.05 (-0.32%) Market Cap $86.6M

Rallybio Corporation · RLYB · NASDAQ

Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases.

Price as of Nov 20, 2026

Key Statistics

82 of 100

MoonshotScore v2 · Rallybio (RLYB)

Exceptional
Business Quality Average (54)
Financial Safety Fortress (99)
Valuation Cheap (81)
Growth Durability Compounding (89)
Momentum Surging (94)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

A fortress balance sheet and elite growth, at a cheap price, though quality is only middling; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.

  • EPS beat 1 of the last 4 reports
  • Altman Z 13.32 · Piotroski F 6
  • ROE 34.5% · ROA -16.8% · current ratio 28.87

Helping: balance-sheet strength, an attractive price, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for RLYB (58 recorded, newest six shown)
RecordedScoreBand
83Exceptional
83Exceptional
83Exceptional
82Exceptional
82Exceptional
82Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$15.47
Change on the day-0.32%
Market capitalisation$86.6M—
Price / earnings (trailing)3.32
Shares traded on the day50.5K

Price & events

Other perspectives

Council score for Rallybio (RLYB): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Neutral
Financial Safety Strong
Valuation Strong
Growth Durability Strong
Momentum Strong

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 21, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Strong
Margin of Safety Undervalued
Profit Margin Strong
Revenue Growth Strong
ROE Strong
Gross Margin Negative

Read on: Nov 20, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

One of these lenses reads this company less favourably than the MoonshotScore does: Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Rallybio (RLYB), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Rallybio Corporation (RLYB) is listed on NASDAQ. It employs 6 people. The market values it at $86.6M.

2 · Latest results

What do the latest results show for Rallybio (RLYB)?

Short answer · as of

Against analyst estimates the company has EPS beat 1 of the last 4 reports.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$212,000$16M$2.84 (diluted)
Q4 FY2025$222,000-$6M—
Q1 FY2026$212,000-$8M-$1.46 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Rallybio (RLYB)?

Short answer

The MoonshotScore pillars rate balance-sheet strength, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 13.32 · Piotroski F 6. Trailing ratios: ROE 34.5% · ROA -16.8% · current ratio 28.87.

5 · Peer comparison

How does Rallybio compare with its peers?

Short answer

Rallybio's score ranks tied for 5th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.45 Nov 19, 2026$475M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$8.76 Nov 20, 2026$521M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.90 Nov 20, 2026$245M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$40.09 Nov 20, 2026$755M88 5-pillar Nov 18, 2026
Rallybio (RLYB) — this page$15.47$86.6M82
ImmuCell Corporation (ICCC) Same industry, near in market value$10.92 Nov 20, 2026$99.3M82 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Named competitor$143.82 Nov 20, 2026$19.3B72 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.69 Nov 19, 2026$160M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.84 Nov 20, 2026$174M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$11.54 Nov 20, 2026$817M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.19 Nov 20, 2026$540M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$7.98 Nov 20, 2026$780M63 5-pillar Nov 18, 2026
Alopexx, Inc. (ALPX) Same industry, near in market value$10.02 Nov 20, 2026$148M61 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 4, 2026

Transactions
52
Identified insiders
10
Purchases
0
Sales
1
Other transactions
51

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held RLYB in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Viking GlobalAndreas HalvorsenQ3 20260.03%$9.02MHeld, unchanged

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Rallybio (RLYB)?

Read these with our analysis →

Rallybio Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the RLYB research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for RLYB?

RLYB carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is RLYB a good stock to buy?

Stock Expert AI does not rate RLYB buy, sell or hold. Rallybio Corporation carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the RLYB stock price today?

The last price recorded for Rallybio Corporation (RLYB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for RLYB?

Rallybio faces several key risks, including the potential failure to obtain regulatory approval for its product candidates, unfavorable clinical trial results, competition from larger pharmaceutical companies, dependence on strategic alliances, and changes in the regulatory landscape. The company's limited financial resources also pose a risk, as it may need to raise additional capital to fund its operations.

What are the key factors to evaluate for RLYB?

Rallybio Corporation (RLYB) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. Rallybio is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Not financial advice.

How frequently does RLYB data refresh on this page?

RLYB's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven RLYB's recent stock price performance?

Rallybio Corporation (RLYB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on rare diseases with unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider RLYB overvalued or undervalued right now?

The trailing P/E of Rallybio Corporation (RLYB) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of RLYB?

Fractional-share availability for Rallybio Corporation (RLYB) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 12 figures on this page — 8 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.